Lymphoma News

The addition of glofitamab-gxbm to gemcitabine and oxaliplatin improved OS among patients with relapsed or refractory diffuse large B-cell lymphoma compared with rituximab, gemcitabine and oxaliplatin, according to the agent’s manufacturer.

MRIs and lumbar punctures may not provide enough therapeutic value to be standard-of-care diagnostic tests in patients suffering neurologic symptoms following chimeric antigen receptor T-cell therapy.

ATLANTA — Enalapril plus standard care was not superior to standard care alone for preventing cardiotoxicity in patients receiving treatment for breast cancer or lymphoma, according to new data from the PROACT trial.

Parents of children with cancer made mental health visits, including those for anxiety and depression, significantly more often than other parents, according to results published in JAMA Network Open.

More than 20% of reported cases of adverse events following bispecific T-cell engager therapies involved a cardiovascular event, findings reported in Journal for ImmunoTherapy of Cancer showed.

Most of the major cancer clinical trial centers in the U.S. are located near more affluent and white populations compared with the national average, according to results published in JAMA Oncology.

The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Researchers at Mayo Clinic have identified clinical factors associated with increased risk for developing myeloid neoplasms following chimeric antigen receptor T-cell therapy, according to data published in JAMA Oncology.

Regardless of vaccination status, individuals with hematologic malignancies had increased odds of developing severe COVID-19 until oral antivirals became widely available in mid-2022, according to data published in JAMA Network Open.

The addition of brentuximab vedotin to lenalidomide and rituximab extended OS among patients with relapsed or refractory diffuse large B-cell lymphoma, according to the agent’s manufacturer.